MX2018001964A - Polipeptidos mrka, anticuerpos y usos de los mismos. - Google Patents

Polipeptidos mrka, anticuerpos y usos de los mismos.

Info

Publication number
MX2018001964A
MX2018001964A MX2018001964A MX2018001964A MX2018001964A MX 2018001964 A MX2018001964 A MX 2018001964A MX 2018001964 A MX2018001964 A MX 2018001964A MX 2018001964 A MX2018001964 A MX 2018001964A MX 2018001964 A MX2018001964 A MX 2018001964A
Authority
MX
Mexico
Prior art keywords
mrka
klebsiella
antibodies
fragments
subject
Prior art date
Application number
MX2018001964A
Other languages
English (en)
Spanish (es)
Inventor
Wang Qun
Xiao Xiaodong
Rajan Saravanan
Shun CHANG Chew-
Heidbrink Thompson Jenny
Yu LIN Hung-
Kendall Stover Charles
Pennini Meghan
Dall'acqua William
S Chowdhury Partha
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2018001964A publication Critical patent/MX2018001964A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2018001964A 2015-08-24 2016-08-23 Polipeptidos mrka, anticuerpos y usos de los mismos. MX2018001964A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US201562238828P 2015-10-08 2015-10-08
PCT/US2016/048221 WO2017035154A1 (en) 2015-08-24 2016-08-23 Mrka polypeptides, antibodies, and uses thereof

Publications (1)

Publication Number Publication Date
MX2018001964A true MX2018001964A (es) 2018-06-19

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001964A MX2018001964A (es) 2015-08-24 2016-08-23 Polipeptidos mrka, anticuerpos y usos de los mismos.

Country Status (16)

Country Link
US (2) US20170073397A1 (enExample)
EP (1) EP3341004A4 (enExample)
JP (1) JP2018527924A (enExample)
KR (1) KR20180042300A (enExample)
CN (1) CN107921086A (enExample)
AU (1) AU2016313653A1 (enExample)
BR (1) BR112018003252A2 (enExample)
CA (1) CA2995387A1 (enExample)
CL (1) CL2018000357A1 (enExample)
CO (1) CO2018001985A2 (enExample)
HK (1) HK1252350A1 (enExample)
IL (1) IL257434A (enExample)
MX (1) MX2018001964A (enExample)
RU (1) RU2018107056A (enExample)
TW (1) TW201718626A (enExample)
WO (1) WO2017035154A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900027XA (en) * 2016-08-05 2019-02-27 Medimmune Llc Anti-o2 antibodies and uses thereof
WO2018075375A1 (en) 2016-10-19 2018-04-26 Medimmune, Llc Anti-o1 antibodies and uses thereof
JP2020525540A (ja) 2017-06-23 2020-08-27 ノソコミアル ヴァクスィーン コーポレイション 免疫原性組成物
CN115838430A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用
CN116813725B (zh) * 2023-07-06 2025-11-04 深圳康泰生物制品股份有限公司 肺炎克雷伯菌的FimA的抗原表位肽及其应用
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2001010386A2 (en) * 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2005034733A2 (en) * 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2152731A2 (en) * 2007-05-02 2010-02-17 Intercell AG Klebsiella antigens
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
WO2012058334A1 (en) * 2010-10-26 2012-05-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Morphology & protein specific reagents as diagnostics for neurodegenerative diseases
SMT202000542T1 (it) * 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas

Also Published As

Publication number Publication date
HK1252350A1 (zh) 2019-05-24
CL2018000357A1 (es) 2018-07-20
JP2018527924A (ja) 2018-09-27
TW201718626A (zh) 2017-06-01
US20170073397A1 (en) 2017-03-16
AU2016313653A1 (en) 2018-04-12
CO2018001985A2 (es) 2018-11-22
IL257434A (en) 2018-04-30
RU2018107056A (ru) 2019-09-26
CN107921086A (zh) 2018-04-17
US20190062411A1 (en) 2019-02-28
EP3341004A1 (en) 2018-07-04
EP3341004A4 (en) 2019-05-15
WO2017035154A1 (en) 2017-03-02
BR112018003252A2 (pt) 2018-09-25
KR20180042300A (ko) 2018-04-25
CA2995387A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
MX2019005426A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
MX2018007406A (es) Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
MX2022002504A (es) Anticuerpos para cd40.
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
PH12016501644B1 (en) Binding proteins and methods of use thereof
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
MX2018001964A (es) Polipeptidos mrka, anticuerpos y usos de los mismos.
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MX2018010672A (es) Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
EA201990895A1 (ru) Антитела к о1 и варианты их применения
WO2018027124A8 (en) ANTI-O2 ANTIBODIES AND USES THEREOF
PH12019501050A1 (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
SI3269735T1 (sl) Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.